TOI Stock Price, The Oncology Institute, . Quote, Chart

Market Summary

USD0.64-0.03

Delayedas of 17 May 2024, 02:03 pm

-4.48%

TOI Stock Price

View Fullscreen

TOI RSI Chart

TOI Valuation

Market Cap

49.8M

Price/Earnings (Trailing)

-0.68

Price/Sales (Trailing)

0.15

EV/EBITDA

-1.4

Price/Free Cashflow

-1.24

TOI Price/Sales (Trailing)

TOI Profitability

EBT Margin

-21.31%

Return on Equity

-176.67%

Return on Assets

-35.67%

Free Cashflow Yield

-80.51%

TOI Fundamentals

TOI Revenue

Revenue (TTM)

342.7M

Rev. Growth (Yr)

24.25%

Rev. Growth (Qtr)

10.35%

TOI Earnings

Earnings (TTM)

-73.0M

Earnings Growth (Yr)

33.7%

Earnings Growth (Qtr)

-6.05%

Breaking Down TOI Revenue

52 Week Range

0.70

(Low)(High)

Last 7 days

-28.4%

Last 30 days

-41.4%

Last 90 days

-65.1%

How does TOI drawdown profile look like?

TOI Financial Health

Current Ratio

3.08

Debt/Equity

2.14

Debt/Cashflow

-0.42

TOI Investor Care

Buy Backs (1Y)

1.38%

Diluted EPS (TTM)

-0.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	342.7M	0	0	0
2023	273.5M	292.8M	309.9M	324.2M
2022	209.6M	220.7M	233.4M	252.5M
2021	191.4M	195.3M	199.1M	203.0M
2020	0	0	0	187.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of The Oncology Institute, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 29, 2024	havencrest healthcare partners, l.p.	sold	-18,310	2.12	-8,637	-
Jan 26, 2024	havencrest healthcare partners, l.p.	sold	-14,935	2.14	-6,979	-
Jan 25, 2024	havencrest healthcare partners, l.p.	sold	-24,595	2.07	-11,882	-
Jan 24, 2024	havencrest healthcare partners, l.p.	sold	-57,304	2.3	-24,915	-
Jan 23, 2024	havencrest healthcare partners, l.p.	sold	-11,263	2.11	-5,338	-
Jan 22, 2024	havencrest healthcare partners, l.p.	sold	-21,757	2.12	-10,263	-
Jan 19, 2024	havencrest healthcare partners, l.p.	sold	-25,530	2.13	-11,986	-
Dec 28, 2023	havencrest healthcare partners, l.p.	sold	-	-	-8,561,050	-
Dec 26, 2023	barasch richard a	acquired	-	-	80,000	-
Dec 26, 2023	o'meara maeve	acquired	-	-	50,000	-

Which funds bought or sold TOI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	unchanged	-	-1,545,620	5,308,880	0.09%
May 15, 2024	STATE STREET CORP	unchanged	-	-46,598	160,054	-%
May 15, 2024	JOSH ARNOLD INVESTMENT CONSULTANT, LLC	sold off	-100	-3,786,910	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-87.88	-59,598	6,171	-%
May 15, 2024	DEUTSCHE BANK AG\	unchanged	-	-4,340	14,907	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-79.04	-245,803	47,631	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-39.77	55.00	2,942	-%
May 15, 2024	Royal Bank of Canada	reduced	-94.68	-2,000	-	-%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	unchanged	-	-	250,000	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	unchanged	-	2,250	6,000	-%

Are Funds Buying or Selling TOI?

Are funds buying TOI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TOI

No. of Funds

Unveiling The Oncology Institute, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 02, 2024	havencrest healthcare partners, l.p.	11.93%	1	SC 13D/A
Nov 07, 2022	havencrest healthcare partners, l.p.	18.9%	1	SC 13D/A

Recent SEC filings of The Oncology Institute, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 02, 2024	DEFA14A	DEFA14A
May 02, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 22, 2024	PRE 14A	PRE 14A
Apr 22, 2024	10-K/A	Annual Report
Apr 03, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report

Peers (Alternatives to The Oncology Institute, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	479.9B	379.5B	11.20%	7.55%	31.24	1.26	12.96%	-25.81%
CI	96.4B	206.0B	-2.18%	28.90%	25.01	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	2.85%	17.20%	15.46	1.27	9.59%	-4.59%
CVS	72.2B	360.9B	-16.66%	-17.14%	9.86	0.2	9.07%	78.49%
CNC	41.2B	155.5B	6.71%	14.75%	15.05	0.26	6.34%	84.42%
UHS	12.0B	14.7B	10.86%	33.14%	14.73	0.82	7.99%	19.23%
DVA	12.0B	12.3B	5.19%	38.43%	14.68	0.97	5.77%	58.74%
MID-CAP
CHE	8.6B	2.3B	-6.84%	5.15%	30.33	3.75	5.96%	18.29%
ACHC	6.2B	3.0B	-6.14%	-7.19%	-547.09	2.07	10.92%	-104.06%
AMEH	2.3B	1.5B	8.58%	22.04%	36.93	1.59	19.34%	40.15%
AMN	2.2B	3.5B	3.96%	-38.10%	15.61	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	13.47%	25.04%	27.49	1.66	11.45%	30.74%
BKD	1.4B	3.0B	11.90%	88.00%	-7.82	0.45	4.98%	4.88%
BEAT	55.6M	-	17.22%	-3.21%	-3.68	-	-	-1.05%
AMS	21.1M	21.6M	17.97%	25.63%	38.19	0.98	9.04%	-50.63%

The Oncology Institute, Inc. News

Latest updates

The Oncology Institute, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	10.3%	94,666,000	85,788,000	82,035,000	80,224,000	76,192,000	71,424,000	64,977,000	60,921,000	55,161,000	52,304,000	52,275,000	49,844,000	48,580,000	-
Operating Expenses	11.4%	112,638,000	101,076,000	95,960,000	95,162,000	109,059,000	96,503,000	85,074,000	79,225,000	73,632,000	93,136,000	54,432,000	50,960,000	50,333,000	53,948,560
S&GA Expenses	1.3%	28,452,000	28,090,000	28,205,000	28,726,000	28,830,000	29,572,000	31,963,000	28,348,000	29,806,000	48,245,000	12,730,000	11,212,000	11,178,000	41,680,688
EBITDA Margin	17.7%	-0.21	-0.26	-0.26	-0.22	-0.19	0.00	0.00	0.01	0.06	-0.04	-0.02	-0.02	-0.06	-0.06
Interest Expenses	-260.1%	-1,985,000	1,240,000	-2,695,000	-2,672,000	-2,650,000	-2,450,000	-1,497,000	-61,000	-74,000	-242,000	-78,000	81,000	101,000	606,013
Income Taxes	100.0%	-	-314,000	135,000	99,000	44,000	-367,000	-24,000	-32,000	180,000	-2,468,000	799,000	780,000	218,000	-505,573
Earnings Before Taxes	-4.3%	-19,889,000	-19,068,000	-17,284,000	-16,798,000	-29,954,000	-11,374,000	-2,698,000	-5,485,000	19,466,000	-12,624,000	-2,181,000	3,985,000	-778,000	-9,015,339
EBT Margin	16.8%	-0.21	-0.26	-0.24	-0.21	-0.18	0.00	-0.01	0.00	0.04	-0.06	-0.04	-0.04	-0.08	-0.08
Net Income	-6.1%	-19,889,000	-18,754,000	-17,419,000	-16,897,000	-29,998,000	-11,007,000	-2,674,000	-5,453,000	19,286,000	-10,156,000	-2,980,000	3,205,000	-996,000	-4.00
Net Income Margin	16.9%	-0.21	-0.26	-0.24	-0.21	-0.18	0.00	0.00	0.00	0.04	-0.05	0.00	0.00	-0.03	-0.03
Free Cashflow	-246.9%	-16,493,000	-4,754,000	-9,240,000	-9,597,000	-17,291,000	-15,992,000	-21,589,000	-11,721,000	-17,983,000	-24,206,000	-3,629,000	-7,537,000	-155,000	650,482

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2020Q1	2019Q4
Assets	-2.3%	205	209	218	230	235	262	284	190	207	203	230	231	203	66.00	231	231	232	232	-
Current Assets	-1.6%	141	143	153	104	119	130	144	112	140	154	0.00	1.00	1.00	30.00	1.00	1.00	2.00	-	0.00
Cash Equivalents	7.7%	36.00	33.00	28.00	29.00	15.00	14.00	61.00	64.00	96.00	115	12.00	15.00	27.00	6.00	1.00	1.00	2.00	-	2.00
Inventory	-15.5%	12.00	14.00	12.00	12.00	10.00	9.00	10.00	9.00	8.00	6.00	6.00	-	-	4.00	-	-	-	-	4.00
Net PPE	1.0%	11.00	11.00	11.00	11.00	10.00	9.00	7.00	6.00	5.00	4.00	4.00	-	-	2.00	-	-	-	-	2.00
Goodwill	0%	7.00	7.00	7.00	7.00	5.00	21.00	0.00	34.00	27.00	27.00	16.00	-	-	14.00	-	-	-	-	-
Liabilities	7.2%	163	152	147	145	136	138	156	66.00	75.00	99.00	25.00	25.00	19.00	38.00	23.00	21.00	18.00	18.00	-
Current Liabilities	31.6%	46.00	35.00	32.00	34.00	30.00	30.00	33.00	36.00	32.00	30.00	4.00	3.00	0.00	29.00	0.00	0.00	0.00	-	0.00
Long Term Debt	1.8%	88.00	87.00	85.00	84.00	82.00	81.00	79.00	-	-	-	-	-	-	7.00	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	0.00	5.00	-	-	5.00	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	87.00	85.00	84.00	82.00	81.00	79.00	-	-	-	-	-	-	7.00	-	-	-	-	-
Shareholder's Equity	-27.6%	41.00	57.00	72.00	85.00	98.00	123	128	124	132	104	48.00	50.00	47.00	28.00	5.00	5.00	5.00	-	42.00
Retained Earnings	-13.6%	-166	-146	-127	-109	-93.08	-63.08	-52.07	-49.40	-43.95	-63.23	-24.90	-24.47	-18.35	-52.31	-21.51	-19.09	-16.47	-16.04	0.00
Additional Paid-In Capital	2.0%	208	204	200	196	191	186	180	173	176	167	0.00	14.00	8.00	80.00	11.00	8.00	6.00	-	0.00
Shares Outstanding	0.2%	74.00	74.00	74.00	73.00	74.00	73.00	73.00	73.00	73.00	73.00	66.00	64.00	63.00	59.00	6.00	-	-	-	-
Float	-	-	-	-	42.00	-	-	-	126	-	-	-	179	-	-	-	173	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4	2018Q3
Cashflow From Operations	-308.0%	-15,883	-3,893	-8,310	-8,660	-15,452	-13,997	-20,399	-10,379	-16,981	-23,335	-2,679	-7,130	464	1,009	-69.42	-402	-28.75	-	-3,283	-
Share Based Compensation	0.2%	4,087	4,079	4,659	4,107	4,965	6,070	6,546	6,514	8,553	24,383	59.00	51.00	42.00	-	-	-	-	-	-	-
Cashflow From Investing	66.7%	19,388	11,627	7,709	24,903	18,401	-32,571	-87,779	-10,262	-1,002	-9,151	-950	-607	-1,446	221,156	-	-	-230,000	-	2,815	-
Cashflow From Financing	47.3%	-938	-1,781	-756	-2,601	-1,709	-847	105,395	-10,685	-1,657	136,128	-8.00	-4,506	22,396	-219,586	-35.12	-1.55	231,511	25.00	-	-
Buy Backs	-	-	-	125	894	-	-	-	9,000	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TOI Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Total operating revenue	$ 94,666,000	$ 76,192,000
Operating expenses
Goodwill impairment charges	0	16,867,000
Selling, general and administrative expense	28,452,000	28,830,000
Depreciation and amortization	1,489,000	1,269,000
Total operating expenses	112,638,000	109,059,000
Loss from operations	(17,972,000)	(32,867,000)
Other non-operating expense (income)
Interest expense, net	1,985,000	1,443,000
Change in fair value of derivative warrant liabilities	0	(143,000)
Change in fair value of earnout liabilities	0	(752,000)
Change in fair value of conversion option derivative liabilities	0	(3,318,000)
Other, net	(68,000)	(143,000)
Total other non-operating (income) loss	1,917,000	(2,913,000)
Loss before provision for income taxes	(19,889,000)	(29,954,000)
Income tax expense	0	(44,000)
Net loss	$ (19,889,000)	$ (29,998,000)
Net loss per share attributable to common stockholders:
Basic (in usd per share)	$ (0.22)	$ (0.33)
Diluted (in usd per share)	$ (0.22)	$ (0.33)
Weighted-average number of shares outstanding:
Basic (in shares)	74,234,287	73,449,132
Diluted (in shares)	74,234,287	73,449,132
Patient services
Revenue
Total operating revenue	$ 52,453,000	$ 50,273,000
Operating expenses
Direct costs	49,497,000	42,814,000
Dispensary
Revenue
Total operating revenue	39,679,000	24,240,000
Operating expenses
Direct costs	32,809,000	19,145,000
Clinical trials & other
Revenue
Total operating revenue	2,534,000	1,679,000
Operating expenses
Direct costs	$ 391,000	$ 134,000

TOI Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 36,055	$ 33,488
Marketable securities	29,777	49,367
Accounts receivable, net	58,760	42,360
Other receivables	368	551
Inventories	11,554	13,678
Prepaid expenses and other current assets	4,678	4,049
Total current assets	141,192	143,493
Property and equipment, net	10,995	10,883
Operating right of use assets	27,416	29,169
Intangible assets, net	17,131	17,904
Goodwill	7,230	7,230
Other assets	568	561
Total assets	204,532	209,240
Current liabilities:
Accounts payable	21,015	14,429
Current portion of operating lease liabilities	6,390	6,363
Accrued expenses and other current liabilities	18,363	13,996
Total current liabilities	45,768	34,788
Operating lease liabilities	25,060	26,486
Derivative warrant liabilities	636	636
Conversion option derivative liabilities	3,082	3,082
Long-term debt, net of unamortized debt issuance costs	88,385	86,826
Other non-current liabilities	273	365
Deferred income taxes liability	32	32
Total liabilities	163,236	152,215
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common Stock, $$0.0001 par value, authorized 500,000,000 shares; 76,046,694 shares issued and $74,312,920 shares outstanding at March 31, 2024 and 75,879,025 shares issued and $74,145,251 shares outstanding at December 31, 2023	8	8
Series A Convertible Preferred Stock, $$0.0001 par value, authorized 10,000,000 shares; 165,045 shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	208,346	204,186
Treasury stock, at cost	(1,019)	(1,019)
Accumulated deficit	(166,039)	(146,150)
Total stockholders’ equity	41,296	57,025
Total liabilities and stockholders’ equity	$ 204,532	$ 209,240

About The Oncology Institute, Inc.

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

WEBSITE	theoncologyinstitute.com
INDUSTRY	Healthcare Plans
EMPLOYEES	750

The Oncology Institute, Inc. Frequently Asked Questions

What is the ticker symbol for The Oncology Institute, Inc.? What does TOI stand for in stocks?

TOI is the stock ticker symbol of The Oncology Institute, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of The Oncology Institute, Inc. (TOI)?

As of Thu May 16 2024, market cap of The Oncology Institute, Inc. is 49.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TOI stock?

You can check TOI's fair value in chart for subscribers.

What is the fair value of TOI stock?

You can check TOI's fair value in chart for subscribers. The fair value of The Oncology Institute, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of The Oncology Institute, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TOI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is The Oncology Institute, Inc. a good stock to buy?

The fair value guage provides a quick view whether TOI is over valued or under valued. Whether The Oncology Institute, Inc. is cheap or expensive depends on the assumptions which impact The Oncology Institute, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TOI.

What is The Oncology Institute, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, TOI's PE ratio (Price to Earnings) is -0.68 and Price to Sales (PS) ratio is 0.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TOI PE ratio will change depending on the future growth rate expectations of investors.